Related Experiment Video

Updated: Feb 26, 2026

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.6K

Regulator of Calcineurin 3 Ameliorates Autoimmune Arthritis by Suppressing Th17 Cell Differentiation

Jin-Sil Park1, Jeong-Hee Jeong1, Jae-Kyeong Byun1

  • 1Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea.

The American Journal of Pathology
|July 14, 2017
PubMed

Insights

Regulator of calcineurin 3 (RCAN3) suppresses inflammatory arthritis by inhibiting Th17 cell differentiation. RCAN3 gene therapy effectively controlled arthritis development and reduced inflammatory markers in vivo.

Area of Science:

  • Immunology
  • Molecular Biology
  • Rheumatology

Background:

  • Regulator of calcineurin 3 (RCAN3) is an endogenous inhibitor of the calcineurin-nuclear factor of activated T cells (NFAT) signaling pathway.
  • RCAN3 modulates calcineurin activity, NFAT nuclear translocation, and downstream signaling.
  • The role of RCAN3 in T-cell regulation and inflammatory arthritis remains to be fully elucidated.

Purpose of the Study:

  • To investigate the impact of RCAN3 on T-cell regulatory function.
  • To determine the effects of RCAN3 on the development and progression of inflammatory arthritis.
  • To explore RCAN3 as a potential therapeutic agent for rheumatoid arthritis.

Main Methods:

  • Studied RCAN3 transfection effects on Th17 cell differentiation in a murine T-lymphoma cell line and primary splenic CD4+ T cells.
  • Utilized RCAN3-overexpression vectors in a collagen-induced arthritis mouse model.
  • Assessed osteoclast formation and inflammatory cytokine expression in vivo.
  • Investigated the effect of antioxidants on RCAN3 expression in vitro.

Main Results:

  • RCAN3 overexpression suppressed Th17 cell differentiation by down-regulating RORγT and up-regulating FOXP3 mRNA.
  • In vivo administration of RCAN3-overexpression vectors controlled arthritis development.
  • RCAN3 injection reduced osteoclast formation and inflammatory cytokine expression.
  • Antioxidants stimulated RCAN3 expression, and combination therapy showed synergistic effects.

Conclusions:

  • RCAN3 plays a significant role in suppressing Th17 cell differentiation and inflammatory responses.
  • RCAN3 gene therapy demonstrates efficacy in controlling collagen-induced arthritis in vivo.
  • RCAN3 holds promise as a novel therapeutic strategy for rheumatoid arthritis.

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

1.3K
Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

9.3K

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.8K
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
17.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
652